Next-Generation Therapy Sonrotoclax Receives FDA Approval
The US Food and Drug Administration (FDA) has approved a new drug, sonrotoclax (brand name Beqalzi), for people with mantle cell lymphoma (MCL) whose disease has returned or stopped responding after at least two prior treatments.
Sonrotoclax works by blocking a protein called BCL‑2 that helps cancer cells survive. In a clinical study of 103 patients who had already tried other therapies — including BTK inhibitors — about half saw their cancer shrink, and many responses lasted over a year.
Why this approval matters
This therapy is significant because it is the first BCL‑2 inhibitor specifically approved for mantle cell lymphoma, offering a new, targeted way to treat the disease. While other drugs in this class, such as venetoclax, have been used in MCL before, they have not been formally approved for this indication. Sonrotoclax also appears designed to be more precise and potentially easier to tolerate than earlier drugs in the same category.
Renewed hope for patients and families
For people living with MCL, each new treatment option matters. The ability of sonrotoclax to produce relatively quick and sustained responses in patients who have already received several therapies suggests it may help extend disease control and improve quality of life.
How this fits into the treatment landscape
The approval is currently limited to the third line of therapy (or beyond), based on the available evidence. Sonrotoclax was approved through an accelerated pathway with the FDA, based on early clinical trial results showing tumor shrinkage and durability of response. Because this data comes from a single study in patients who had already received multiple treatments — and not from large head‑to‑head comparisons with existing second‑line therapies — regulators typically approve such drugs first for later use. Ongoing studies will help determine whether the drug may be appropriate earlier in the course of treatment.
Overall, this approval represents continued momentum in MCL research and expands the growing set of tools available to patients and their care teams.
Sources
- AJMC — Sonrotoclax Granted Accelerated Approval for R/R Mantle Cell Lymphoma
- Cancer Network — FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
- OncLive — FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
- Targeted Oncology — FDA Approves Next-Gen BCL2 Inhibitor Sonrotoclax for R/R Mantle Cell Lymphoma